Associations between osteoporosis and drug exposure: A post-marketing study of the World Health Organization pharmacovigilance database (VigiBase®)

被引:11
|
作者
Batteux, Benjamin [1 ,2 ,3 ,4 ]
Bennis, Youssef [1 ,3 ]
Bodeau, Sandra [1 ,3 ]
Masmoudi, Kamel [1 ]
Hurtel-Lemaire, Anne-Sophie [1 ]
Kamel, Said [3 ,5 ]
Gras-Champel, Valerie [1 ,3 ]
Liabeuf, Sophie [1 ,3 ]
机构
[1] Amiens Univ, Dept Pharmacol, Med Ctr, F-80054 Amiens, France
[2] St Quentin Med Ctr, Dept Rheumatol, F-02321 St Quentin en Yvelines, France
[3] Jules Verne Univ Picardie, MP3CV Lab, EA7517, F-80054 Amiens, France
[4] Amiens Picardie Univ, RECIF, Med Ctr, F-80054 Amiens, France
[5] Amiens Univ, Biochem Lab, Med Ctr, F-80000 Amiens, France
关键词
Osteoporosis; Drug; Pharmacology; Pharmacoepidemiology; Pharmacovigilance; BONE-MINERAL DENSITY; RHEUMATOID-ARTHRITIS PATIENTS; LOW-DOSE METHOTREXATE; POSTMENOPAUSAL WOMEN; FRACTURE RISK; VITAMIN-A; PSYCHOTROPIC MEDICATIONS; INADEQUATE RESPONSE; MULTIPLE-SCLEROSIS; SIGNAL GENERATION;
D O I
10.1016/j.bone.2021.116137
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Bone remodeling is a complex process, and many conditions (including drug exposure) lead to osteoporosis. Here, we sought to detect new disproportionality signals for drugs associated with osteoporosis. Methods: We performed a disproportionality analysis of the World Health Organization's VigiBase (R) pharmacovigilance database through April 12, 2020. The frequency of reports on osteoporosis for all identified drug classes was compared with that for all other drugs and quoted as the reporting odds ratio (ROR) [95% confidence interval (CI)]. Results: Of the 7,594,968 cases spontaneously recorded to VigiBase (R), 4758 concerned osteoporosis. New disproportionality signals with a pharmacologically plausible mechanism were found for drugs used in neurology (levodopa (ROR [95%CI]: 10.18 [4.33-25.10]), selective serotonin agonists (4.22 [2.34-7.00]) and memantine (4.10 [1.56-8.93])), hematology (romiplostim (4.93 [1.15-21.10])), pulmonology (macitentan (3.02 [1.84-4.90])), ophthalmology (ranibizumab (3.31 [1.00-10.51])) and rheumatology (tofacitinib (3.65 [3.00-4.40])). The robustness of these new results is supported by the significant RORs for the vast majority of drugs already known to induce osteoporosis and/or increase the fracture risk, namely glucocorticoids, gonadotropin-releasing hormone analogs, anti-aromatases, androgen receptor blockers, thyroid hormones, proton pump inhibitors, thiazolidinediones, vitamin K antagonists, loop diuretics, protease inhibitors, nucleoside and nucleotide reverse transcriptase inhibitors, and enzyme-inducing antiepileptics including barbiturates and derivatives, hydantoin derivatives, carboxamide derivatives and fatty acid derivatives. Conclusion: We established up a comprehensive list of drugs potentially associated with osteoporosis and highlighted those with pharmacologically plausible mechanisms leading to bone fragility. Our results might pave the way for additional exploration of these mechanisms.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] A Post-Marketing Drug Evaluation Framework Based on Real-World Electronic Health Records Data
    Wang, Yu
    Ma, Shuang
    Ru, Hua
    Ni, Hongyi
    Li, Jingsong
    MEDINFO 2023 - THE FUTURE IS ACCESSIBLE, 2024, 310 : 134 - 138
  • [42] PCSK9 Inhibitors and Infection-Related Adverse Events: A Pharmacovigilance Study Using the World Health Organization VigiBase
    Park, Dahyun
    Bea, Sungho
    Bae, Ji-Hwan
    Lee, Hyesung
    Choe, Young June
    Shin, Ju-Young
    Kim, Hoon
    DRUGS-REAL WORLD OUTCOMES, 2024, 11 (03) : 465 - 475
  • [43] Fetal and Neonatal Adverse Drug Reactions Associated with Biologics Taken During Pregnancy by Women with Autoimmune Diseases: Insights from an Analysis of the World Health Organization Pharmacovigilance Database (VigiBase(R))
    Dernoncourt, Amandine
    Liabeuf, Sophie
    Bennis, Youssef
    Masmoudi, Kamel
    Bodeau, Sandra
    Laville, Solene
    Hurtel-Lemaire, Anne-Sophie
    Gras-Champel, Valerie
    Batteux, Benjamin
    BIODRUGS, 2023, 37 (01) : 73 - 87
  • [44] Associations of neuralgic amyotrophy with COVID-19 vaccination: Disproportionality analysis using the World Health Organization pharmacovigilance database
    Kim, Jee-Eun
    Park, Jin
    Min, Young Gi
    Hong, Yoon-Ho
    Song, Tae-Jin
    MUSCLE & NERVE, 2022, 66 (06) : 766 - 770
  • [45] Antineoplastic Drug-induced Aortitis: An Unraveled Adverse Effect Using the World Health Organization Pharmacovigilance Database
    Mettler, Camille
    Chouchana, Laurent
    Terrier, Benjamin
    JOURNAL OF RHEUMATOLOGY, 2020, 47 (08) : 1298 - 1300
  • [46] Drug-induced spontaneous coronary artery dissection: Analysis of the World Health Organization's pharmacovigilance database
    Gautier, Paul
    Khouri, Charles
    Galinier, Michel
    Elbaz, Meyer
    Montastruc, Francois
    ARCHIVES OF CARDIOVASCULAR DISEASES, 2025, 118 (02) : 133 - 135
  • [47] A post-marketing pharmacovigilance study of avapritinib: Adverse event data mining and analysis based on the United States Food and Drug Administration Adverse Event Reporting System database
    Rong, Li
    Xie, Mengyuan
    Jiang, Manxue
    Qiu, Hongyu
    Kong, Lingti
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 (08) : 1816 - 1826
  • [48] Post-marketing safety of pimavanserin: a real-world pharmacovigilance study based on the FDA adverse event reporting system (FAERS)
    Liu, Dong
    Zhang, Xueni
    Xu, Haiyan
    EXPERT OPINION ON DRUG SAFETY, 2025,
  • [49] Post-marketing pharmacovigilance study of inclisiran: mining and analyzing adverse event data from the FDA Adverse Event Reporting System database
    Zou, Dan
    Hu, Qiaozhi
    Liu, Ying
    Yu, Lei
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2024, 46 (06) : 1419 - 1426
  • [50] Safety of sugammadex for reversal of neuromuscular block: A postmarketing study based on the World Health Organization pharmacovigilance database
    Lyu, Qiang
    Ye, Pei
    Zhang, Hewei
    Ye, Xiaofei
    Zheng, Yi
    Xu, Jinfang
    Chen, Xiao
    Chen, Chenxin
    Guo, Xiaojing
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (02) : 449 - 457